FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

PHOENIX, Dec. 26, 2017 -- (Healthcare Sales & Marketing Network) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution... Biopharmaceuticals, FDA INSYS Therapeutics, cannabidiol, Prader-Willi Syndrome

Source: HSMN NewsFeed - December 26, 2017 Category: Pharmaceuticals Source Type: news